scorecardresearch
Sunday, August 17, 2025
TopicDiabetes

Topic: Diabetes

Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.

India had highest number of diabetics in the world in 2022, 62% were not on medication—Lancet report

Study conducted by NCD Risk Factor Collaboration (NCD-RisC) and WHO. Findings part of first global analysis of trends in both diabetes rates and treatment across countries.

Danish scientists create ‘smart’ insulin with ‘on-off’ switch to target blood sugar highs & lows

Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.

Fried, baked, ultra-processed foods fuel India’s diabetes epidemic—1st-of-its-kind study by ICMR & MDRF

Study published in International Journal of Food Sciences and Nutrition says having foods low in advanced glycation end products can mitigate burden of obesity-linked type 2 diabetes.

How semaglutide is emerging as A-Z drug, helping with diabetes, alcohol cravings & more

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.

Chinese scientists see sweet success, reverse type-1 diabetes in woman using her own stem cells

Study in journal Cell says fat cells were extracted from the patient & altered to develop into any type of cell in the body. She has been insulin-independent for a yr, the 1st such case.

Yoga, dual therapies — 1st India-specific guidelines for those with both hypertension & diabetes

Key feature of guidelines is emphasis on using multiple methods to measure hypertension, including home BP monitoring. For the first time, yoga is recommended as an adjunct therapy

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Mega-selling weight-loss & diabetes drug now shown to reduce risk of kidney failure, deaths

Semaglutide once a week reduced risk of adverse outcomes in kidney patients by 24 percent, finds study published in The New England Journal of Medicine.

What’s the 1-hour plasma glucose test & can it detect diabetes risk more accurately

International Diabetes Federation recommends 1-hr plasma glucose test, a more sensitive & practical method. A 1-hPG value of 209 mg/dL or more indicates Type 2 diabetes.

On Camera

SC’s stray dog order lit a match in Delhi. Are they a menace or companions?

The last time this matter flared up was when Delhi Chief Minister Rekha Gupta, in a very similar directive in April, called for the relocation of stray dogs in the capital.

Modi’s ‘Diwali bonanza’ for the common man—next-gen GST reforms, lower tax on daily-use items soon

Finance ministry says the proposed revamp will focus on structural reforms, rate rationalisation & ease of living, & will be deliberated upon in the coming weeks.

What is Project Sudarshan Chakra, announced by Modi from ramparts of Red Fort

The project is meant to be a ‘protective shield that will keep expanding’, the PM said. It is on the lines of the ‘Golden Dome’ announced by Trump, it is learnt.

War of IAF, PAF doctrines: As Pakistan obsesses over numbers, India embraces risk, wins

Now that both IAF and PAF have made formal claims of having shot down the other’s aircraft in the 87-hour war in May, we can ask a larger question: do such numbers really matter?